Building contingency plans for an ambiguous post-Brexit market
One company's positive approach to Brexit preparations, despite the lack of definition.
Despite a lot of discussion surrounding Brexit and Parliament’s recent vote to remain as part the EMA, there remains a lot of ambiguity and a lack of clear advice for the UK’s pharmaceutical industry. So, it is not a surprise that many businesses in the UK are yet to undertake the necessary work to build contingency plans that will ensure their medicines can continue to be licensed for sale in mainland Europe no matter what the eventual outcomes are of leaving the EU. Colin Newbould, director of regulatory affairs and QP services, Wasdell Group, provides Part II of CPHI Online's focus on Brexit and its effect on the UK pharmaceutical industry.
"As a contract services provider headquartered in the UK, we have been developing a strategic approach that will allow us to continue business-as-usual-across the globe regardless of the final decisions surrounding Brexit.
"Ultimately, despite requiring a lot of time and resource, the potential impact of Brexit has presented us with an interesting opportunity. It has given us the chance to review and refine our manufacturing, clinical and commercial operations and develop new ways to support more life-cycle management. For example, our new facility in Ireland will open later this year and it will allow us to carry out any necessary importation testing for our customers supplying to the EU. The new facility means that although our headquarters will remain in the UK, our operations and quality systems will continue to meet EU GMP standards as a minimum. The increased capacity will also help us to cater for increasing customer demand for our clinical and packaging services.
"As a result of this forward-planning we already have short, medium and longer term plans in development for many of our customers. These plans include a range of measures such as safety stock building to remove pressure from supply chains, changing contractual derogated responsibilities, changing importation sites and ultimately ensuring full technical transfer to our new facility as and when required.
"For companies that are yet to embark upon their Brexit preparations, we recommend actively engaging with all customers, sharing guidance, support and facts. So long as uncertainty prevails, strategic decisions around post-Brexit operations will be delayed which will inevitably have an impact on supply chains. Regulators and politicians need to offer clear guidance as soon as possible, while drug makers and contract services providers should be doing their best to prepare for every outcome."
As the director of regulatory affairs and QP services at The Wasdell Group, Colin is responsible for developing and implementing the company strategy to ensure world-class compliance, effective processes and customer satisfaction. Along with his position as director of QP services, he is also one of Wasdell’s QPs for certification to the European market. Colin holds a BSc in Chemistry with Analytical Chemistry and Toxicology and is a current management committee member of the Pharmaceutical and Healthcare Sciences Society (PHSS) and has previous terms with the Pharmaceutical Quality Group (PQG).
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance